Spruce Biosciences CMO departing Dec 31; Kirk Ways named interim CMO

SPRUCE BIOSCIENCES, INC.

Dr. Ralph Charlton III's employment ends Dec 31, 2024; severance includes $343,200 lump sum plus 9 months COBRA.
Dr. Kirk Ways (73), Board member since June 2021, appointed interim CMO effective Dec 20, 2024.
Ways previously served as interim CMO of MBX Biosciences and Development Head at Janssen.
Severance amount equals 9 months of base salary at $343,200 paid as lump sum.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.